60.00 EGP

Purchase this product now and earn 60 Points!


CABERGAMOUN 2TAB; cabergoline, hormonal agents .


calbergoline 0.5 mg .


inhibition/ suppression of physiological lactation : cabergamoun is inddicated for the inhibition of physiological lactation soon after delievry and for suppression of already established lactation : 1- after parturition , when the mother elects not to breast feed the infant or when breast feeding is contraindicated due to medical reasons releated to the mother or the new-born . 2- after stillbrith or abortion . cabergamoun prevents / supresses physiological lactation by inhibition prolactin secretion . in controlled clinical trials , cabergoline given as a single 1 mg administration during the first day post-partum , was effective in inhibiting milk secretion , as well as breast engorgement and pain in 70-90% of the women . less than 5% of women experienced rebound breast symptomatology during the third post-partum week ( which was usually mild in severity ) . suppression of milk secretion and relief of breast engorgement and pain are obtained in approximately 85% of nursing women treated with a total dose of 1 mg cabergamoun given in four divided doses over two days . rebound breast symptomatology after day 10 is uncommon ( approximately 2% of cases ) . treatment of hyperprolactinaemic disorders : cabergamoun is indicated for the treatment of dysfunctions associated with hyperprolactinaemia , including amenorrhoea , oligomenorrhoea , onovulation and galactorrhoea . cabergamoun is indicated in patients with prolactin -secreting pituitary adenomas ( micro – and macroprolactatinomas ) , idiopathic hyperprolactinaemia or empty sell syndrome with associated hyperprolactinaemia , which represent the basic underlying pathogenies contributing to the above clinical manifestations . on chronic therapy cabergamoun at doses ranging between 1 and 2 mg per week , was effective in normalising serum prolactin levels in approximately 84% of hyperprolactinaemic patients . regular cycles were resumed in 83% of previously amennohoeic women . restoring of ovulation was documented in 89% of women with progesterone levels monitored during the luteal phase . galactorrhoea disappeared in 90 % of cases showing this symptom before therapy . reduction in tumour size was obtained in 50-90 % of female and male patients with micro – or macroprolactinoma.


Follow all directions given to you by your pharmacist or doctor carefully . They may differ from the information contained in this leaflet

Ask your pharmacist or doctor for help if you do not understand the instructions on the box .

The recommended dose is : –

to be administrered by the oral route .since in clinical studies cabergoline has been mainly administered with food and since the tolerabilitiy of this class of compounds is improved with food , it is recommended that catergamoun be preferably taken with meals for all the therapeutic indications . inhibition /suppression of physiological lactation : for inhibition of lactation cabergamoun should be administered during the first day post -patrum .the recommended therapeutic dose is 1 mg “( two 0.5 mg tablets ) given as a single dose . for suppression of established lactation the recommended therapeutic dosage regimen is 0.25 mg ( one-half 0.5 mg tablet ) every 12 hours for two days ( 1 mg total dose ) . this dosage regimen has be demonstrated to be better tolerated than the single dose regimen in women electing to suppress lactation having a lower inicdence of adverse enevents , in particular of hypotensive symptoms . treatment of hyperolactinaemic disorders : the recommended initial dosage of cabergamoun is 0.5 mg per week given in one or two ( one half of one 0.5 mg tablet ) doses ( e.g on monday and thursday ) per week . the weekly dose should be increased gradually , preferably by adding 0.5 mg per week at monthly intervals until an optimal therapeutic response is achieved . the therapeutic dosage is usually 1 mg per week and ranges from 0.25 mg to 2 mg per week . the maximum dose should not exceed 3 mg per day . the weekly dose may be given as a single administration or divided into two or more doses per week are to be given since the tolerability of doses greater than 1 mg taken as a single weekly ( dose has been evaluated only in a few patients . patients should be evaluated during dose escalation to determine the lowest dosage that produces the therapeutic response . monitoring of serum prolactin levels at monthly intervals is advised since , once the effective therapeutic dosage regimen has been reached , serum prolactin nomalisation is usually observed within two to four weeks . after cabergamoun withdrawal , recurrence of hyperolactinaemia is usually observed . however , persistent suppression of prolactin levels has been observed for several months in some patients . of the group of women followed up , 23/29 had ovulatory cycles which continued for greater than 6 months after cabergamoun discontinuation . use in children : the safety and efficacy of cabergamoun has not been established in subjects less than 16 years of age . use in elderly : as a consequence of the indications for which cabergamoun is presently proposed , the experience in elderly is very limited . available data do not indicate a special risk .


symptoms of overdose would likely be those of over-stimulation of dopmine receptors e.g nausea , vomiting gastric complaints , postural hypotension , confusion /psychosis or hallucinations . Supportive measures should be taken to remove and unabsorbed drug and maintain blood pressure , if necessary . in addition , the administration of dopamine antagonist drugs may be advisable .


hypersensitivity to cabergamoun , any excipient of the product or any ergot alkaloid . History of pulmonary , pericardial and retroperitoneal fribrotic disorders . cabergamoun is contraindicated in patients with hepatic insufficiency and with toxaemia of pregnancy . cabergamoun should not be co-administered with anti-psychotic medications or administrated to women with a history of puerperal psychosis . for long term treatment : evidence of cardiac valvulopathy as determined by pre-treatment echocardiography .


Store at temperature not exceeding 25 °C. Cabergamoun tablets absorb moisture, so you should always keep it in dry place.
Carton box contains ( All / white opaque PVC/PVDC ) strip of 2 tablets in packaging 1, 2, 3 strips with enclosed leaflet.
AMOUN PHARMACEUTICAL CO . S.A.E. El-Obour City, Cairo, Egypt.

Additional information



How to use

Reviews (0)


There are no reviews yet.

Show reviews in all languages (1)

Be the first to review “CABERGAMOUN 2TAB”

Your email address will not be published.

Shopping Cart
Don`t copy text!
Scroll to Top
60.00 EGP
Purchase this product now and earn 60 Points!